Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New screening could open door to T-Cell therapy for Hard-to-Treat cancers

NCT ID NCT05812027

Knowledge-focused Sponsor: TScan Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study screens up to 1,150 people with advanced solid tumors like head and neck, cervical, or lung cancer. Researchers test blood and tumor samples to see if participants have the right genetic markers for future T-cell therapy trials. The goal is to find who might benefit from these experimental treatments, but no therapy is given in this study.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this screening could help identify patients who may benefit from future T-cell therapies for solid tumors.
What could go wrong
This is only a screening study, not a treatment. It does not test any therapy, so there is no direct benefit to participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2023

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The purpose of this study is to identify participants with locally advanced (unresectable) or metastatic solid tumors that could potentially be eligible for a TScan clinical study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Willing and able to provide written informed consent. * Male or female aged ≥18 years at the time of signing the informed consent. * Have one of the following histologically or cytologically confirmed locally advanced (unresectable) or metastatic solid tumor for which the Sponsor has an associated clinical study: * Head and neck cancer * Cervical cancer * Non-small cell lung cancer * HPV positive anogenital cancers * Sarcoma * Other cancers with a reasonable likelihood of expressing 1 or more antigens included in a TScan clinical trial, following approval by the TScan Medical Monitor or their delegate. * Willing to provide a buccal swab for HLA testing * Willing to provide a saliva sample to use as a normal control for the LOH assay * Have access to an adequate FFPE tumor block that is \<8 months old or is willing to provide a fresh core-needle biopsy from a location deemed safe by the treating medical team. Exclusion Criteria: • Participants undergoing anticancer therapy with curative intent such as tumor surgical resection with or without neoadjuvant/adjuvant therapy, or definitive chemoradiation, unless they have locoregionally advanced disease and are expected to have a high risk of relapse after their curative intent therapy as determined by the treating investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adenocarcinoma carcinoma cervical cancer head and neck cancer Head and Neck Neoplasms human papillomavirus-related squamous cell carcinoma non-small cell lung carcinoma nut midline carcinoma sarcoma squamous cell carcinoma Uterine Cervical Neoplasms uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervical cancer Head and neck cancer HPV16 related cancers Non-small cell lung cancer Nut carcinoma Sarcoma Uveal melanoma

Contacts and locations

Locations

  • Allegheny Hospitals Network

    Pittsburgh, Pennsylvania, 15224, United States

  • Baylor College of Medicine

    Houston, Texas, 77030, United States

  • Columbia University Herbert Irving Comprehensive Cancer Center

    New York, New York, 10032, United States

  • HonorHealth Research and Innovation Institute

    Scottsdale, Arizona, 85258, United States

  • Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • Memorial Healthcare System

    Hollywood, Florida, 33021, United States

  • Norton Cancer Institute

    Louisville, Kentucky, 40202, United States

  • OU Health Stephenson Cancer Center

    Oklahoma City, Oklahoma, 73104, United States

  • Oncology Hematology Care

    Cincinnati, Ohio, 45242, United States

  • Orlando Health

    Orlando, Florida, 32806, United States

  • Providence Cancer Institute Franz Clinic

    Portland, Oregon, 97213, United States

  • Sarah Cannon Research Institute

    Nashville, Tennessee, 37203, United States

  • The Cleveland Clinic

    Cleveland, Ohio, 44195, United States

  • University of California San Diego

    San Diego, California, 92037, United States

  • University of Chicago

    Chicago, Illinois, 60637, United States

  • University of Miami, Sylvester Comprehensive Cancer Center

    Miami, Florida, 33136, United States

  • University of Minnesota, Masonic Cancer Center

    Minneapolis, Minnesota, 55455, United States

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina, 27599, United States

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15232, United States

  • University of South Florida

    Tampa, Florida, 33606, United States

  • Yale Cancer Center

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.